Bendectin and Birth Defects: The Challenges of Mass Toxic Substances Litigation

by

Write The First Customer Review

Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabilities would result in precedent-setting litigation. Before it was over, the Benedictin litigation would involve 2,000 claimants over a fifteen-year period. Michael D. Green offers a comprehensive overview of the Benedictin case and ...

Bendectin and Birth Defects: The Challenges of Mass Toxic Substances Litigation 1998, University of Pennsylvania Press, Philadelphia

ISBN-13: 9780812216455

Revised edition

Trade paperback

Select
Bendectin and Birth Defects: The Challenges of Mass Toxic Substances Litigation 1996, University of Pennsylvania Press, Philadelphia, PA

ISBN-13: 9780812232578

Hardcover

Select